(Q36623644)

15 August 2017

1 reference

title

Autologous stem cell transplantation beyond 60 years of age. (English)

1 reference

15 August 2017

Jantunen E

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

16 October 2006

1 reference

Bone Marrow Transplantation

15 August 2017

published in

1 reference

15 August 2017

volume

38

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

715-720

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705514

15 August 2017

exact match

0 references

cites work

Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol. Cooperative Group of Study and Treatment of Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

The Influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Autologous blood and marrow transplantation in patients 60 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

High-dose intravenous melphalan: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

Palifermin for oral mucositis after intensive therapy for hematologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Cardiac systolic function before and after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Peripheral stem cell mobilization and engraftment in patients over age 60

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

An elective single autograft with high-dose melphalan: single-center study of 451 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Stem cell mobilisation in lymphoproliferative diseases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Characterization and outcome of "hard to mobilize"' lymphoma patients undergoing autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705514

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705514

1 reference

15 August 2017

1 reference